XOMA Corp (NASDAQ:XOMA) major shareholder Bvf Partners L. P/Il acquired 3,797 shares of the firm’s stock in a transaction that occurred on Monday, May 13th. The stock was acquired at an average price of $14.36 per share, for a total transaction of $54,524.92. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Large shareholders that own more than 10% of a company’s stock are required to disclose their sales and purchases with the SEC.
XOMA stock traded up $1.27 during trading on Thursday, hitting $16.09. The stock had a trading volume of 1,717 shares, compared to its average volume of 53,229. XOMA Corp has a 1-year low of $11.02 and a 1-year high of $25.99. The company has a market capitalization of $127.38 million, a price-to-earnings ratio of -10.12 and a beta of 2.38. The company has a current ratio of 7.20, a quick ratio of 7.20 and a debt-to-equity ratio of 1.13.
XOMA (NASDAQ:XOMA) last announced its earnings results on Monday, May 6th. The biotechnology company reported $0.21 earnings per share for the quarter, beating the consensus estimate of ($0.12) by $0.33. XOMA had a negative net margin of 48.62% and a negative return on equity of 51.66%. The firm had revenue of $8.13 million during the quarter, compared to the consensus estimate of $3.23 million. As a group, research analysts predict that XOMA Corp will post -1.18 earnings per share for the current year.
XOMA has been the topic of several recent research reports. ValuEngine lowered shares of XOMA from a “hold” rating to a “sell” rating in a research report on Wednesday, May 1st. HC Wainwright set a $30.00 price objective on shares of XOMA and gave the stock a “buy” rating in a research report on Friday, April 12th. Wedbush set a $25.00 price objective on shares of XOMA and gave the stock a “buy” rating in a research report on Tuesday. Finally, Zacks Investment Research upgraded shares of XOMA from a “sell” rating to a “hold” rating in a research report on Saturday, March 9th. One research analyst has rated the stock with a sell rating, two have given a hold rating and two have given a buy rating to the company. XOMA has a consensus rating of “Hold” and a consensus target price of $24.57.
ILLEGAL ACTIVITY NOTICE: This report was first posted by Markets Daily and is the property of of Markets Daily. If you are accessing this report on another publication, it was stolen and reposted in violation of U.S. & international copyright laws. The correct version of this report can be read at https://www.themarketsdaily.com/2019/05/16/xoma-corp-xoma-major-shareholder-buys-54524-92-in-stock.html.
XOMA Company Profile
XOMA Corporation, a biotech company, discovers and develops therapeutic candidates in the United States, Europe, and the Asia Pacific. The company has a pipeline of monoclonal antibodies and technologies to license to pharmaceutical and biotechnology companies to further their clinical development. Its proprietary product candidates include X213, an allosteric inhibitor of prolactin action; XMetA, an insulin receptor-activating antibody to provide long-acting reduction of hyperglycemia in Type 2 diabetic patients; IL-2, a therapy for metastatic melanoma and renal cell carcinoma; and PTH1R, an anti-parathyroid receptor pipeline to address unmet medical needs, including primary hyperparathyroidism and humoral hypercalcemia of malignancy.
Recommended Story: What is the QQQ ETF?
Receive News & Ratings for XOMA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for XOMA and related companies with MarketBeat.com's FREE daily email newsletter.